INTRODUCTION
============

Obstructive sleep apnea (OSA) is a relevant health problem because of its high prevalence in the general population and its significant morbidity and mortality[@r1]^-^[@r5]. Continuous positive airway pressure (CPAP) is a cost-effective treatment commonly prescribed in patients with OSA since it reduces daytime sleepiness, rates of motor vehicle accidents, and blood pressure[@r6]^-^[@r9]. Polysomnography in the sleep laboratory has been recommended for the diagnosis of OSA and CPAP titration[@r10]^,^[@r11]. Given this approach challenges the capacity of sleep laboratories and health system resources[@r12], the need for low cost and less time-consuming diagnostic procedures becomes imperative. Since OSA treatment provides many benefits to patients, it is important to develop simpler strategies (than traditional PSG) for prompt diagnosis and access to treatment. In this regard, pulse oximetry has been extensively evaluated as an alternative diagnostic tool for OSA. Though, published guidelines are controversial as to whether oximetry can be used to diagnose and indicate CPAP treatment in patients with clinical suspicion of OSA[@r13]^,^[@r14].

There is scarce information on whether a model based on clinical history and oximetry is a suitable approach to decide CPAP treatment in adult patients with suspicion of OSA[@r15]. We hypothesized that physicians experienced in the treatment of sleep-related breathing disorders could indicate a CPAP trial in patients with clinical suspicion of OSA and abnormal oximetry with low chance of error (by error we mean prescribing CPAP to patients who do not they required such treatment). Therefore, the aim of this large multicenter study was to assess the accuracy of CPAP treatment indication based on clinical and nocturnal oximetry data compared with PSG. The secondary objective was to evaluate predictors of CPAP indication among the observers who based their decision on pulse oximetry.

METHODS
=======

This was a retrospective multicenter observational study involving seven sleep laboratories in five large cities of Argentina: Ciudad Autónoma de Buenos Aires (Hospital Alemán, Hospital Británico, Hospital de Clínica), Córdoba (Centro Dr. Lázaro Langer), Mendoza (Instituto Médico Insares), Salta (Hospital Privado Santa Clara de Asis) and Paraná (Centro Privado de Medicina Respiratoria de Paraná). It was approved by the Ethics Committee of Hospital Alemán.

Patient selection
-----------------

On a database of 761 patients (304 women) studied in the Hospital Aleman's sleep laboratory between 2013 and 2015, an intentional sampling was carried out in order to have a similar proportion of men and women with a hypopnea apnea index (AHI) less than 5 and with mild, moderate and severe OSA. Patients over 18 years of age who had undergone PSG and filled out a standardized sleep questionnaire (SQ) were preselected. Exclusion criteria were: patients with a total sleep time of less than 180 minutes, PSG with CPAP titration, oximetry with artifacts by disconnections or finger probe displacement more than 5% of total recording time, subjects with suspected narcolepsy or central sleep apnea by PSG[@r16] and patients who did not complete the questionnaire or chose two answers in some of the questions. 411 patients were included in the study. [Figure 1](#f1){ref-type="fig"} shows the flow chart for patient selection.

Figure 1Flow chart for patient selection (PSG = Polysomnography; SQ = Sleep Questionnaires; TST = Total Sleep Time).

Measurements
------------

The patients selected for this study had a PSG with a computerized polysomnographic system (Akonic, Buenos Aires, Argentina) which included: electroencephalogram (F4/A1, C4/A1, O2/A1), electrooculogram, chin electromyogram, leg electromyogram, electrocardiogram, airflow by nasal pressure and an oral thermistor, thoracic and abdominal movements (piezoelectric sensors), snoring, SO2 and body position. PSG interpretation was performed according to published criteria[@r17]. OSA was defined as an apnea/hypopnea index (AHI) ≥ 5. Pulse oximetry from PSG was recorded using a finger probe (Nonin, OEM III) and the data storage rate was 1 Hz. Nail polish was removed to avoid interferences in SO~2~ readings. Software on PSG performed automatic SO~2~ analysis and excluded areas with artifacts (artifact time). Then, the program calculated the oxygen desaturation index (ODI) ≥ 3% (ODI3: mean number of O~2~ desaturations ≥ 3% per hour of valid analyzed recording) using the valid total recording time (total recording time - artifact time). ODI3 was selected to assess pulse oximetry as it has shown the best intraclass correlation coefficient with AHI and therefore could be used as surrogate for AHI[@r18]. Pulse oximetry suggestive of OSA was defined as the presence of a sawtooth pattern in one or more sectors of the oxygen saturation curve plus an oxygen desaturation index ≥ 3% (ODI3) \> 5[@r19].

Upon arrival to the sleep lab, the patients completed a standardized sleep questionnaire (SQ) that included the Spanish versions of the Epworth Sleepiness Scale (ESS)[@r20], the Berlin questionnaire[@r21]^,^[@r22], relevant medical history and medication.

Comorbidities such as hypertension, coronary disease, ischemic or hemorrhagic stroke or diabetes type II, were considered when patients reported them, or if they received any medication for their condition. Restless leg syndrome was assumed when patients complained of unpleasant sensations in the lower limbs before sleeping and reported behaviors to alleviate them. Tiredness was regarded as a symptom when it was described on a daily basis. Insomnia was defined both as difficulty falling asleep or waking up while sleeping and delay in returning to sleep more than 5 times a month.

Study procedure
---------------

The database with all the information necessary for decision making was available on a website specifically designed for this research. Researchers could access it through username and password to see clinical data, questionnaires, oximetry or PSG data and treatment decision options.

Three to six months before starting the study, all researchers received written instructions to access and use the website tools so that they could train with twenty clinical cases to understand work dynamics. To help decide treatment with CPAP, all observers used a summary sleep questionnaire (SSQ). Eight physicians with at least 10 year experience in the management of patients with sleep-related breathing disorders independently logged onto a website and were blinded to any patient identification data or indication of CPAP. Seven observers (one per center) who could only access the clinical data (SSQ), curve and pulse oximetry results were collectively referred to as the test method (Os-SO~2~), while the eighth observer, who also had full access to all indicators of PSG, was the reference method (O-PSG). Once observers assessed the information available on the website, they had to choose between three CPAP treatment options ("yes", "no" or "do not know"). The term "do not know" could be selected when the observers had doubts in the prescription of CPAP or could not make the decision with the information available. Observers 1 to 7 could indicate CPAP treatment if the patients met clinical criteria and their oximetry was compatible with OSA. O-PSG and Os-SO2 supported CPAP treatment decision on their experience and current published guidelines[@r23]^,^[@r24].

Statistical analysis
--------------------

According to the distribution of the variables, the mean and standard deviation or the median and the percentiles 25-75% were reported. Differences between proportions were calculated by Chi Square test.

The accuracy of the Os-SO~2~ (test method) for the indication of CPAP was evaluated by calculating the sensitivity (S), specificity (Sp), positive and negative likelihood ratio (PLR, NLR) in each observer for both the total group and the more or less symptomatic patients. The more symptomatic patients were defined as the presence of Epworth greater than 10 and / or at least one comorbidity, while the less symptomatic subjects were those with an Epworth less than 11 and without comorbidities[@r25].

Multiple logistic regression analysis was used to assess the association between CPAP indication most frequently made by Os-SO2 in each patient (depending variable: CPAP: 1 = Yes, 0 = No/Do not know) and age, gender (1 = Male, 0 = Female), BMI, sleepiness (1 = ESS \> 10, 0 = ESS \< 11), comorbidities (1 = Yes, 0 = No), insomnia (1 = Yes, 0 = No), restless leg syndrome (1 = Yes, 0 = No) and ODI3 ≥ 15 (1 = ODI3 ≥ 15, 0 = ODI3 \< 15) (independent variables). ODI3 ≥ 15 was chosen because this cut-off point has shown good performance to diagnose moderate to severe OSA[@r19]. The statistical analysis was performed with the following software programs: MedCalc Software, Version 18, Mariakerke, Belgium.

RESULTS
=======

Of 761 potentially eligible patients, 350 were excluded for different reasons (see [Figure 1](#f1){ref-type="fig"}). Thus, there were 411 patients for the final analysis ([Figure 1](#f1){ref-type="fig"}). The characteristics of the study population are shown in [Table 1](#t1){ref-type="table"}. The median age was 54 years, 55.5% (228) were men, 76.4% (314) had OSA (AHI ≥ 5), and 31.4% (129) were obese. As for OSA severity categories, similar percentages were found: no OSA (23.6%), mild OSA (23.8%), moderate OSA (25.6%) and severe OSA (27%) (*p* 0.8). ESS \> 10 was present in 38.2% of patients and tiredness was reported by 54%.

###### 

Characteristics of the study population.

  Patient number                       411
  ------------------------------------ -----------------------
  Male                                 224 (54.5)
  Female                               187 (45.5)
  Age (years)                          54 (42 - 64)
  Body mass index (BMI kg./m^2^)       27.8 (24.7 - 31.2)
  Prevalence of OSA (AHI ≥ 5)          314 (76.4)
  Epworth                              9 (6 - 13)
  Epworth \> 10                        157 (38.2)
  Tiredness                            222 (54)
  Comorbidities                         
  \- Hypertension                      135 (32.9)
  \- Coronary heart disease            22 (5.35)
  \- Ischemic or hemorrhagic stroke    9 (2.2)
  \- Diabetes type II                  101 (24.6)
  Restless leg syndrome                107 (24.6)
  Insomnia                             114 (27.8)
  Polysomnography                       
  \- TRT (total recording time, min)   395.5 (383.5 - 420)
  \- TST (total sleep time, min.)      334.4 (298.7 - 362.7)
  \- SE (sleep efficiency)             85 (79 - 90)
  \- TNREM (min.)                      277.3 (249.9 - 302.4)
  \- TREM (min.)                       53 (37.3 - 69.3)
  \- AHI (Apnea/Hypopnea Index)        16.5 (6.2 - 32)
  \- T90 (%)                           2.2 (0.2 - 12.1)
  \- SO2 median (%)                    92.8 (91.5 - 94.2)
  \- ODI3                              9.6 (3.8 - 20.8)
  Severity of OSA (%)                   
  \- AHI ≥ 5 - \< 15                   98 (23.8)
  \- AHI ≥ 15 - \< 30                  105 (25.6)
  \- AHI ≥ 30                          111 (27)

Data are presented as median (25-75 % percentiles), or n (%). TNREM: total stages N1+N2+N3; TREM: total amount of REM sleep. ODI3: oxygen desaturation index ≥ 3%. T90 (%): percentage of TRT at SO2 \< 90%.

[Table 2](#t2){ref-type="table"} shows the patients´ characteristics according to symptoms. The more symptomatic patients (ESS \> 10 or one comorbidity) were older and presented a higher prevalence of obesity, tiredness, insomnia and RLS compared to the less symptomatic subjects. On the other hand, OSA prevalence, its severity, and oximetry parameters were similar in both groups.

###### 

Comparison of more or less symptomatic patients.

                                       More symptomatic     Less symptomatic      p
  ------------------------------------ -------------------- --------------------- ----------
  Patient number (%)                   276 (67.1)           135 (32.8)            \< 0.001
  Male %                               48.2                 67.4                  0.0002
  Age (years)                          57 (46 - 66)         48 (38 - 58)          \< 0.001
  Body mass index (BMI kg./m^2^)       28.1 (24.7 - 31.6)   27.6 ( 24.7 - 29.8)   0.10
  Obesity %                            35.6                 8.9                   \< 0.001
  Prevalence of OSA % (AHI ≥ 5)        74.6                 80                    0.23
  Epworth                              11 (6 - 15)          7 (4 - 8)             \< 0.001
  Tiredness %                          60.1                 41.5                  \< 0.001
      Restless leg syndrome %          34.8                 4                     \< 0.001
      Insomnia %                       30.8                 21.5                  0.048
  Polysomnography                                                                  
  \- TRT (total recording time, min)   397 (384 - 420)      395 (381 - 416)       0.3
  \- TST (total sleep time, min.)      334 (302 - 363)      334.5 (295 - 361)     0.76
  \- SE (sleep efficiency)             0.85 (0.78 - 0.9)    0.85 (0.8 - 0.89)     0.63
  \- TNREM (min.)                      277.3 (251 - 304)    277 (246 - 298)       0.48
  \- TREM (min.)                       52.4 (37.4 - 69.3)   53.3 (37.3 - 69.4)    0.78
  \- AHI (Apnea/Hypopnea Index)        17.4 (4.6 - 33.3)    14.5 (7.2 - 28.2)     0.42
  \- T90 (%)                           2.6 (0.2 - 15.6)     1.6 (0.1 - 7.7)       0.15
  \- SO2 median (%)                    92.8 (91.3 - 94)     92.8 (91.9 - 94.4)    0.08
  \- ODI3                              9.6 (3.8 - 23.7)     9.4 (3.3 - 19.6)      0.38
  Severity of OSA                                                                  
  \- AHI ≥ 5 - \< 15 %                 20.6                 30.4                  0.03
  \- AHI ≥ 15 - \< 30 %                25                   26.7                  0.71
  \- AHI ≥ 30 %                        29                   23                    0.2

Data are presented as median (25-75 % percentiles), or n (%). TNREM: total stages N1+N2+N3; TREM: total amount of REM sleep. ODI3: oxygen desaturation index ≥ 3%; T90 (%): percentage of TRT at SO2 \< 90%.

O-PSG indicated CPAP to 225 subjects (54.7%) of which 85% presented moderate to severe OSA (AHI median 29, interquartile range 19 - 43) and 80% had either sleepiness or at least one comorbidity.

S, Sp and PLR / NLR for Os-SO~2~ are shown in [Table 3](#t3){ref-type="table"}. In the whole group (WG), Os-SO~2~ had average S, Sp and PLR of 61.7%, 93.4% and 19.3, respectively. Os-SO~2~ had lower S, greater Sp and PLR for CPAP indication in more symptomatic patients than those with fewer symptoms (mean S: 60 *versus* 68%, *p* 0.046; mean Sp: 98.4 *versus* 88%, *p*\<0.01; mean PLR: 38.9 *versus* PLR 10, *p*\<0.01).

###### 

AUC-ROC, sensitivity, specificity and positive/negative likelihood ratios from Os-SO~2~

  ----------------------------------------------------------------------------------- ----------------- -------------------- ------------- -------------------- ------------- ------------------- ------------- -------------------
  **Whole group (n = 411)**                                                                                                                                                                                     

  **Os-SO~2~**                                                                        **Sensitivity**   **Specificity**      **PLR**       **NLR**                                                              

                                                                                      **Range**         **Mean (CI 95%)**    **Range**     **Mean (CI 95%)**    **Range**     **Mean (CI 95%)**   **Range**     **Mean (CI 95%)**

  O1 - O7                                                                             45.3 - 78.7       61.7 (49.3 - 74.1)   81.7 - 98.4   93.4 (87.1 - 99.7)   5.3 - 34.7    18.3 (7.7 - 29)     0.26 - 0.56   0.4 (0.29 - 0.52)

  **More symptomatic patients (Epworth \> 10 or at least one comorbidity) (n=276)**                                                                                                                             

  **Specificity**                                                                     **Sensitivity**   **Specificity**      **PLR**       **NLR**                                                              

                                                                                      **Range**         **Mean (CI95%)**     **Range**     **Mean (CI95%)**     **Range**     **Mean (CI95%)**    **Range**     **Mean (CI95%)**

  O1 - O7                                                                             44.7 - 75.4       60 (48 - 72)         93.8 - 100    98.4\                12.2 - 71.5   38.9 (17.6 - 60)    0.26 - 0.55   0.4 (0.29 - 0.52)
                                                                                                                                           (96.2 - 100)                                                         

  **Less symptomatic patients (Epworth \< 11 without comorbidities) (n=135)**                                                                                                                                   

  **Os-SO~2~**                                                                        **Sensitivity**   **Specificity**      **PLR**       **NLR**                                                              

                                                                                      **Range**         **Mean (CI95%)**     **Range**     **Mean (CI95%)**     **Range**     **Mean (CI95%)**    **Range**     **Mean (CI95%)**

  O1 - O7                                                                             44.7 - 87         68 (53 - 83)         68.5 - 96.6   88 (77 - 99)         2.9 - 14.2    10 (4.8 - 15.4)     0.18 - 0.54   0.35 (0.2 - 0.48)
  ----------------------------------------------------------------------------------- ----------------- -------------------- ------------- -------------------- ------------- ------------------- ------------- -------------------

Os-SO~2~: observers who use the clinical history and oximetry to indicate CPAP (O1 - 7); CI95%: confidence interval 95%; PLR/NLR: positive and negative likelihood ratio.

Two Os-SO~2~, reported the highest number of false positive (FP) and negative (FN) cases. [Table 4](#t4){ref-type="table"} compares FP and FN with true negative (TN) and positive (TP) cases. FP patients showed an AHI, an ODI3, and a BMI higher than TN cases. On the other hand, FN cases had an AHI, an ODI3 and a lower BMI than TP subjects. TP and TN subjects had a clearly abnormal oximetry (sawtooth pattern and mean ODI3 34) or one without cyclical variations in the SO2 curve (mean ODI3 1.4).

###### 

Characteristics of false positive and negative patients of whole group (O4 and O5)

  ------------------ ---------------------------- --------------------------- ----------
                     **Observer 4**                                           
  **Variables**      **False positive (n=34)**    **True negative (n=152)**   **p**
  AHI                16.3 (11.3 - 21.1)           3 (1.1 - 7.8)               \< 0.001
  -AHI \< 5          3 (8.8)                      \-                          \-
  -AHI ≥ 5 - \< 15   11 (32.4)                    \-                          \-
  -AHI ≥ 15          20 (58.8)                    \-                          \-
  BMI (Kg/m^2^)      27.1 (25.7 - 29.7)           25.2 (22.5 - 28.1)          0.0073
  Tiredness          13 (38.2)                    73 (48)                     0.3
  Epworth \> 10      5 (14.7)                     48 (31.6)                   0.049
  Comorbidities      1 (2.9)                      57 (37.5)                   \< 0.001
  ODI3               10 (7.3 - 15.5)              1.4 (1.4 - 4.7)             \< 0.001
                     **Observer 5**                                           
  **Variables**      **False negative (n=123)**   **True positive (n=102)**   **p**
  AHI                21.2 (14.1 - 29)             45.5 (32.7 - 57.1)          \< 0.001
  -AHI \< 5          0 (0)                        \-                          \-
  -AHI ≥ 5 - \< 15   32 (26)                      \-                          \-
  -AHI ≥ 15 - \<30   64 (52)                      \-                          \-
  -AHI ≥ 30          27 (22)                      \-                          \-
  Tiredness          80 (65)                      56 (54.9)                   0.12
  BMI (Kg/m^2^)      28.4 (25.7 - 31.6)           31.2 (28.4 - 35.1)          \< 0.001
  Epworth \> 10      51 (41.5)                    53 (52)                     0.12
  Comorbidities      76 (61.8)                    62 (60.8)                   0.88
  ODI3               12.2 (7.9 - 16.9)            34.4 (25.5 - 48)            \< 0.001
  ------------------ ---------------------------- --------------------------- ----------

Data are presented as median (25-75% percentiles) or percentage (%). AHI: Apnea/Hypopnea Index; ODI3: oxygen desaturation index ≥ 3%.

[Table 5](#t5){ref-type="table"} shows the predictors of CPAP indication. An ODI3 ≥ 15 was the most powerful predictor used for therapeutic decision making (OR: 145, 95%CI 57 - 366, *p*\<0.0001). Also, being male (OR: 2.56, 95% CI 1.1 - 5.9, *p* 0.026, having a higher BMI (OR: 1.14, 95% CI 1.03 - 1.25, *p* 0.0064), an ESS \> 10 (OR: 2.5, 95%CI 1.04 - 6.1, *p* 0.04) and some comorbidities (OR: 3.2, 95%CI 1.35 - 7.6, *p* 0.0082) were independently associated with CPAP indication.

###### 

Predictors of CPAP indication from Os-SO~2~.

  Parameters                            Coefficient   Std. Error   Odds ratio           p
  ------------------------------------- ------------- ------------ -------------------- -----------
  Dependent variable: CPAP indication                                                   
  Independent variables                                                                  
  -Age                                  0.013         0.016        1.01 (0.98 - 1.04)   0.40
  -BMI                                  0.13          0.047        1.14 (1.04 - 1.25)   0.0064
  -Gender                               0.94          0.42         2.5 (1.12 - 5.9)     0.0265
  -Epworth \> 10                        0.93          0.45         2.5 (1.04 - 6.1)     0.04
  -Tiredness                            0.55          0.46         1.73 (0.7 - 4.2)     0.23
  -Comorbidities                        1.16          0.44         3.2 (1.35 - 7.6)     0.0082
  -Insomnia                             0.025         0.49         1.03 (0.39 - 2.7)    0.96
  -Restless leg Syndrome (RLS)          0.43          0.53         1.5 (0.54 - 4.3)     0.42
  -ODI3 ≥ 15                            5             0.47         145 (57 - 366)       \< 0.0001

Os-SO~2~: observers who use the clinical history and oximetry to indicate CPAP.

We assess the direct costs of an initial approach based on oximetry or polysomnography, knowledge (guidelines) and experience of physicians to indicate CPAP treatment in more symptomatic patients. For this, we considered the decision of treatment with CPAP most frequently made by Os-SO~2~, which had 80 false-negative subjects and no false positive case, and the average costs in the local market. Based on these data, we could have saved US\$ 24200 ([Table 6](#t6){ref-type="table"}).

###### 

Cost-benefit analysis of an initial diagnostic approach with polysomnography or oximetry.

  Initial diagnostic strategy                         n     Unit price ^a^   Final cost ^a^    
  --------------------------------------------------- ----- ---------------- ---------------- -----------
  **1) Polysomnography**                                                                       
  First visit                                         411   15               6165              
  Polysomnography                                     411   200              82200             
  Second visit                                        411   15               6165              
  CPAP trial (auto-CPAP)                              225   150              33750             
  **Total cost**                                                             **128280**        
  **2) Nocturnal oximetry**                                                                    
  First visit                                         411   15               6165              
  Nocturnal oximetry (more symptomatic patients)      276   50               13800             
  Polysomnography (less symptomatic patients)         135   200              27000             
  Second visit                                        411   15               6165              
  CPAP trial (auto-CPAP) (more symptomatic)           99    150              14850             
  CPAP trial (auto-CPAP) (less symptomatic)           46    150              6900              
  Polysomnography (more symptomatic without CPAP                                               
  indication by oximetry)                             80    200              16000             
  Third visit                                         80    15               1200              
  CPAP trial (auto-CPAP) in false negative cases by                                            
  oximetry                                            80    150              12000             
  **Total cost**                                                             **104080**        
  **Cost savings**                                                                            **24200**

n: number of studies. a: expressed as US \$ dollars

DISCUSSION
==========

The main finding of this multicenter study was that a strategy based on clinical history and pulse oximetry allowed sleep specialists to reliably indicate CPAP treatment for approximately 60% of the more symptomatic patients who required such therapy according to clinical criteria and PSG. This approach showed varying sensitivity in Os-SO~2~, both in the total group (45 - 79%) and subgroups of more (45 - 75%) or less symptomatic (45 - 87%) patients. This interobserver heterogeneity possibly reflects the complexity of the CPAP treatment decision-making procedure, which involves a wide range of variables, such as symptoms (sleepiness or tiredness being the most important), associated comorbidities and physician´s experience with OSA patients and the interpretation of pulse oximetry. In our patient population, the pretest probability, (i.e. CPAP recommendation by PSG) was 55% in the total group, 65% in the more symptomatic patients and 34% in those with fewer symptoms. Depending on the PLR, the posttest probability of obtaining a true positive diagnosis ranged from 60 to 90% in oligosymptomatic subjects, 80 to 97% in the total group and 95 to 99% in the more symptomatic patients[@r26]. Although the CPAP indication rate varied among Os-SO~2~ observers, Sp was similar (94 to 100%, *p* 0.7) and PLR was greater than 10 in more symptomatic patients. The low proportion of false positive subjects makes this approach a consistent tool. In our cohort, observer 4 showed the highest number of FP cases. However, when analyzing these 34 cases, 30 patients could have had CPAP indication according to the published guidelines[@r24], since 20 had moderate OSA and 10 were mild forms of OSA with associated symptoms. Thus, there were only 4 cases who did not really require CPAP. Eventually, a CPAP trial could have only caused minor side effects without serious risk to the patient. Also, during the CPAP trial, treatment adherence and response are tested, and if necessary, the treatment mode could be changed. The drawback with an initial diagnostic approach based on nocturnal oximetry in the entire patient sample was that there were an average of 40% of false negative cases (i.e., O-PSG indicated CPAP but Os-SO~2~ did not). In this way, patients suspected of obstructive sleep apnea but with inconclusive oximetry would require a second diagnostic sleep study with the consequent potential increase in costs and treatment delay. Despite these disadvantages, if this strategy had been adopted only in more symptomatic patients, the health costs could have been reduced by almost 20% compared to the traditional polysomnography-based approach (see [Table 6](#t6){ref-type="table"}).

We recently published[@r15] a study where two blind independent physicians agreed on CPAP therapy according to PSG (gold standard) or oximetry (alternative method) results and symptoms. The S was higher (80 - 92%) and the Sp similar (92 - 96%) to the current study. The differences between both studies could be related to population differences (moderate to severe OSA: 70% *vs.* 52%), the number of observers who participated in both studies (seven *versus* one) and the fact that observers´ decisions were based exclusively on CPAP treatment guidelines without resorting to their experience.

Our results are in line with previous clinical validation studies of oximetry. Mulgrew et al.[@r27] showed that in patients with a Sleep Apnea Clinical Score ≥ 15, Epworth ≥ 10 and ODI4 ≥ 15, an ambulatory approach based on auto-CPAP plus oximetry was similar to PSG in terms of CPAP titration and clinical outcomes. Antic et al.[@r28] observed that in patients with frequent snoring plus ESS ≥ 8 and ODI3 \> to 27, a nurse model of care based on oximetry and auto-CPAP showed similar results to physician care based on PSG in terms of clinical improvement and adherence to CPAP treatment. Similarly, Chai-Coetzer et al.[@r29] demonstrated treatment under a primary care model compared with a specialist model did not result in worse sleepiness scores, quality of life or CPAP compliance in patients with high pretest for moderate to severe OSA (clinical score ≥ 5, ODI3 ≥ 16 and ESS \> 7 or persistent hypertension with 2 or more drugs). These findings are consistent with NICE guidelines which state that moderate to severe OSA can be diagnosed through clinical history and pulse oximetry performed at the patient's home[@r30].

This study has several strengths. It is a multicenter study of a large sample of patients and a similar number of men and women. Also, the proportion of subjects without or with mild, moderate or severe OSA was similar. All patients had a standardized sleep questionnaire and a PSG. Finally, the observers who participated were blind and the therapeutic decision to or not to treat with CPAP was based on each observer´s knowledge and experience so as to simulate a real-life scenario. However, this clinical research presents some limitations. First, its retrospective design and selection bias limits its generalization. Second, this simple strategy requires training in the management of patients with sleep apnea and analysis of oximetry, therefore it cannot be extrapolated to general practitioners or primary care physicians.

In conclusion, a tool based on clinical data and pulse oximetry allowed to indicate CPAP treatment reliably in most symptomatic patients with suspicion of OSA. This approach would be useful in the initial management of OSA when access to specialized sleep medicine centers is limited for different reasons. Future studies are necessary to confirm these results in a real life scenario.
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